Evidence map›Paper›PMID 36792082›Full record

ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2023

[Recent Progress of Nano-drug Combined with Chimeric Antigen Receptor T Cell 
Therapy in the Treatment of Soild Tumors].

Yi Liu, Ning Li, Wenyang Jiang, Qing Geng

Open access · greenAbstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Yi LiuDepartment of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, China.
Ning LiDepartment of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, China.
Wenyang JiangDepartment of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, China.
Qing GengDepartment of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, China.
Renmin Hospital of Wuhan University · CNWuhan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric antigen receptor T cell (CAR-T) therapy has shown remarkable success in treating hematological malignancies. However, CAR-T therapy for solid tumors is still limited due to the unique solid-tumor microenvironment and heterogeneous target antigen expression, which leads to an urgent need of combining other therapies. At present, nano delivery system has become one of the most promising directions for the development of anti-tumor drugs. Based on the background of CAR-T and tumor treatment, we focus on the research progress of nanomedicine combined with CAR-T therapy, and systematically review the strategies and examples in recent years in the aspects of in vivo delivery of mRNA, regulation of tumor microenvironment, combination with photothermal therapy. And we also look forward to the future direction of this filed.
.

Indexed as

Lung NeoplasmsNanoparticlesNeoplasmsReceptors, Chimeric AntigenAntigens, NeoplasmHumansPharmaceutical PreparationsT-LymphocytesTumor MicroenvironmentAntigens, NeoplasmPharmaceutical PreparationsReceptors, Chimeric AntigenChimeric antigen receptor T cell therapyNano delivery systemSolid tumors

Identifiers

PMID36792082
PMCPMC9987048
OpenAlexW4321004427

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.